Recent News
Feb 23, 2024
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
Events and presentations
Mar 04, 2024
Cowen 44th Annual Health Care Conference
Feb 15, 2024
Blueprint Medicines 4Q and Full Year 2023 Earnings Conference Call
Our commitment to patients
At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
read onMeet the Blue Crew
Meet the Blue Crew
Pablo Sierra, Director, Iberia and UK, Global Medical Affairs
I am part of the International Medical Affairs Team, responsible for leading the Medical Affairs function on a national level across Spain, Portugal and the UK with a growing team of highly talented people. Our goal is to ensure timely patient access to our transformative medicines by being the bridge between the company and the external scientific/medical community, from early stages of clinical development to commercialization and beyond.
Read onWe aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit Our Blueprint.
read on“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Kate Haviland, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Kate Haviland, Chief Executive Officer
Dare to be different
We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.
read on